Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 23;12(1):38.
doi: 10.1186/1475-2867-12-38.

Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting

Jiangning Zhao #  1 , Zhenshu Xu #  2 , Delong Liu  3 , Quanyi Lu  1
Affiliations

Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting

Jiangning Zhao et al. Cancer Cell Int. .

Abstract

Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard frontline regimen for diffuse Large B -cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL remains uncertain. FCR (fludarabine, cyclophosphamide, rituximab) has been shown to be better than fludarabine alone and fludarabine plus cyclophosphamide for IL. In FOLL05 trial, R-CHOP was compared with R-CVP (cyclophosphamide, vincristine, prednisone) and R-FM (fludarabine, mitoxantrone). The study showed that R-CHOP appears to have the best risk-benefit ratio for IL. The StiL NHL1 trial showed that BR (bendamustine, rituximab) has longer progression free survival and is better tolerated than R-CHOP. Long-term complications with secondary malignancies between the two regimens appear to be comparable. In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma.

PubMed Disclaimer

References

    1. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000;51(6):634–641. doi: 10.1046/j.1365-3083.2000.00745.x. - DOI - PubMed
    1. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63(8):803–843. doi: 10.2165/00003495-200363080-00005. - DOI - PubMed
    1. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA. et al.Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(19):3121–3127. doi: 10.1200/JCO.2005.05.1003. - DOI - PubMed
    1. Coiffier B. Rituximab in diffuse large B-cell lymphoma. Clinical advances in hematology & oncology: H&O. 2004;2(3):156–157. - PubMed
    1. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26(25):3603–3613. doi: 10.1038/sj.onc.1210376. - DOI - PubMed